Research outlook

Where metastatic prostate cancer treatment is heading

Metastatic prostate cancer · Updated Nov 15, 2026

Prostate cancer that has spread is treated first with hormone therapy: testosterone suppression (ADT) plus a stronger hormone pill such as abiraterone, enzalutamide, apalutamide or darolutamide, sometimes with docetaxel chemotherapy. Men now live years longer than a decade ago. When the cancer stops responding to hormones (castration-resistant), options include PARP inhibitors for DNA-repair gene changes, Lu-PSMA-617 radioligand therapy, radium-223, and chemotherapy. Research is moving these treatments earlier and testing new hormone-pathway drugs and immune approaches.

  1. Now

    Nov 2026

    PARP inhibitors move earlierHappened 45.8 months median survival

    Niraparib delayed progression in hormone-sensitive disease with DNA-repair changes; talazoparib plus enzalutamide extended survival to 45.8 vs 37.0 months.

    45.8: months median survival, vs 37.0 with enzalutamide alone.

    Radioligands move earlierHappened 28% lower risk of progression

    Lu-PSMA-617 added to first hormone therapy cut the risk of progression by 28%; radium-223 plus enzalutamide extended survival.

    28%: lower risk of progression or death with Lu-PSMA-617 added.

    Long-term hormone therapy resultsHappened 50% alive at 8 years

    In ENZAMET, 50% of men on enzalutamide were alive at 8 years vs 40%.

    50%: alive at 8 years, vs 40% with the older drug.

  2. 6 months

    by May 2027

    Talazoparib in hormone-sensitive diseaseLikely 45.8 months median survival (later stage)

    Pfizer's TALAPRO-3 (599 men with DNA-repair changes) finished its main follow-up in February 2026; results are expected.

    45.8: months median survival in castration-resistant disease, vs 37.0.

    An EZH2 inhibitor with enzalutamidePossible

    Pfizer's MEVPRO-1 (609 men) compares mevrometostat plus enzalutamide with chemotherapy or another hormone drug after abiraterone; due February 2027.

    Capivasertib with docetaxelPossible 33.2 months without progression (earlier stage)

    AstraZeneca's CAPItello-280 (1,035 men) tests capivasertib with chemotherapy in castration-resistant disease; its main follow-up ended March 2026.

    33.2: months without progression in PTEN-deficient disease, vs 25.7.

  3. 12 months

    by Nov 2027

    A next-generation PARP inhibitorPossible

    AstraZeneca's EvoPAR-PR01 (1,898 men) adds saruparib to hormone therapy at diagnosis, for men with or without DNA-repair changes; due September 2027.

    Androgen receptor degradersPossible

    Bristol Myers Squibb's rechARge (960 men) tests BMS-986365, which breaks down the androgen receptor, against a switch of hormone drug or docetaxel; due September 2027.

  4. 3 years

    by late 2029

    Blocking hormone production at the sourcePossible

    Merck's OMAHA trials (about 2,600 men) test opevesostat, which shuts down the first step in making all steroid hormones; due 2028.

    Antibody-drug conjugates and T-cell engagersPossible 42.4% PSA fell by half (early trial)

    Merck's ifinatamab deruxtecan trial (due June 2028) and J&J's pasritamig trial (due August 2028) target B7-H3 and KLK2.

    42.4%: had PSA fall by at least half in an early trial.

  5. 5 years

    by late 2031

    Smarter sequencing of treatmentsPossible

    TRIPLE-SWITCH (due March 2031) tests docetaxel before switching hormone drugs; saruparib is tested after earlier hormone therapy (due May 2031).

    Lu-PSMA as part of first treatmentLong shot 28% lower risk of progression

    If PSMAddition shows a survival benefit, radioligand therapy could join hormone therapy at diagnosis for PSMA-positive disease.

    28%: lower risk of progression or death with Lu-PSMA-617 added.

Happened Likely Possible Long shot

The research paths

Maturing

PARP inhibitors and gene testing

45.8 months median survival
Details and 3 trialsHide
Heating up

Radioligand therapy

28% lower risk of progression
DetailsHide

Radioactive drugs that seek out PSMA or bone. Lu-PSMA-617 is moving from late to first treatment.

WatchPSMAddition survival data.

Heating up

New hormone-pathway drugs

33.2 months without progression
Details and 7 trialsHide
Early

Immune and antibody approaches

42.4% PSA fell by half
Details and 2 trialsHide

T-cell engagers aimed at KLK2 or STEAP1, and antibody-drug conjugates aimed at B7-H3.

WatchKLK2-comPAS; I-DXd trial.

Active

Using chemotherapy better

Details and 1 trialsHide

Trials testing when docetaxel helps most alongside modern hormone pills.

WatchTRIPLE-SWITCH.

Borrowed from other cancers

From Breast cancer

Capivasertib

Phase 3

An AKT inhibitor approved for HR-positive breast cancer with PI3K pathway changes.

From Small cell lung cancer

Ifinatamab deruxtecan (I-DXd)

Phase 3

A B7-H3 antibody-drug conjugate first developed in small cell lung cancer.

From Ovarian and breast cancer

Niraparib and talazoparib

Approved

PARP inhibitors first approved for BRCA-related ovarian and breast cancers.

Open to join now

See every recruiting Metastatic prostate cancer trial →

When the trials finish

Completion dates the trials registered. Results usually follow 3 to 12 months later.

2026202720282029203020312032Today
Feb 2026
Mar 2026
Feb 2027
Saruparib, hormone-sensitive (EvoPAR-PR01)PARP inhibitors and gene testing
Sep 2027
Sep 2027
Sep 2027
Ifinatamab deruxtecan vs docetaxelImmune and antibody approaches
Jun 2028
Pasritamig, late-line (KLK2-comPAS)Immune and antibody approaches
Aug 2028
Sep 2028
Nov 2028
May 2031

What just happened

Lu-PSMA-617 added to first hormone therapy delays progression

PSMAddition, The Lancet.

Enzalutamide benefit holds at 8 years

ENZAMET, Annals of Oncology.

Niraparib plus abiraterone delays progression with DNA-repair changes

AMPLITUDE, Nature Medicine.

Standard treatment today

How to read this page, and sourcesHow to read this page, and sources

See Metastatic prostate cancer trials recruiting now →

Last reviewed 2026-11-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.